Results 181 to 190 of about 47,580 (341)

Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study

Haemophilia, EarlyView.
ABSTRACT Background The Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Haemophilia (ATHN 7) monitors use of contemporary haemophilia therapies, including emicizumab, a bispecific antibody substituting for activated factor (F)VIII in people with haemophilia A (HA).
Tyler W. Buckner, Shannon L. Carpenter, Nabil Daoud, Christine L. Kempton, Lucy Lee, Lynn Malec, Thomas W. McLean, Paul Morton, Carrie O'Neill, Janice M. Staber, Michael Wang, Stacy E. Croteau, Michael Recht   +12 more
wiley   +1 more source

Post‑Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients With Congenital Haemophilia A With Inhibitors

Haemophilia, EarlyView.
ABSTRACT Introduction The bispecific monoclonal antibody emicizumab was approved for prophylactic treatment of congenital haemophilia A (HA) in Japan in 2018. Aim To monitor long‐term safety and effectiveness of emicizumab, including appropriate concomitant use of bypassing agents (BPAs), in Japanese patients with congenital HA with inhibitors who ...
Midori Shima, Katsuyuki Fukutake, Masanori Matsumoto, Yoshihiko Sugimura, Chiaki Sugita, Lyu Ji, Mika Kawano, Tadashi Matsushita   +7 more
wiley   +1 more source

Integration of Efanesoctocog Alfa in Clinical Practice for Children, Adolescents, and Young Adults With Severe Haemophilia A

Haemophilia, EarlyView.
ABSTRACT Introduction Efanesoctocog alfa is a novel, “ultra‐extended half‐life” FVIII concentrate for bleed treatment and prevention in haemophilia A. Clinical trials excluded individuals with active or prior FVIII inhibitors, those on emicizumab, and previously untreated patients (PUPs).
Debbie Jiang, Natalie Johnston, Daniel Echelman, Stacy E. Croteau   +3 more
wiley   +1 more source

Outcomes of Emicizumab Treatment for Haemophilia A Paediatric Patients: A Systematic Review With Meta‐Analysis

Haemophilia, EarlyView.
ABSTRACT Introduction Haemophilia A in paediatric patients presents a lifelong risk of spontaneous and trauma‐induced haemorrhage, leading to progressive joint damage, disability and impaired quality of life. Emicizumab, a bispecific monoclonal antibody administered subcutaneously, offers sustained haemostatic protection and has shown promising ...
Konstantina Bolou, George Triantafyllou, Athina Dettoraki, Aikaterini Michalopoulou, Miltiades Kyprianou, Olympia Papakonstantinou, Helen Pergantou   +6 more
wiley   +1 more source

Systematic characterization of lysine glucuronidation in a bispecific antibody. [PDF]

MAbs
Reyda MR, Ji Q, Huang M, Sokolowska I, Yan Q, Mulholland J, Mo J, Hu P.   +7 more
europepmc   +1 more source

Reference Values for the Haemophilia Joint Health Score in Patients With Severe Haemophilia Derived From the Canadian Bleeding Disorder Registry

Haemophilia, EarlyView.
ABSTRACT Background People with haemophilia (PwH) are at increased risk of joint bleeding, often leading to haemophilic arthropathy. The Haemophilia Joint Health Score (HJHS) is widely used to evaluate joint health, but its interpretability is limited by the lack of age‐based reference values.
Khang T. Nguyen, Anthony K. C. Chan, Davide Matino, Emma Iserman, Arun Keepanasseril, Karen Strike   +5 more
wiley   +1 more source

Recent advances in bispecific antibody-drug conjugates for breast cancer therapy. [PDF]

Cancer Chemother Pharmacol
Ji X, Yang Y, Ma C, Huang W, Guo S, Wang L, Zheng H, Wu X.   +7 more
europepmc   +1 more source

Targeting of peripheral blood T lymphocytes [PDF]

, 1996
Bolhuis, R.L.H. (Reinder), Gratama, J.W. (Jan-Willem), Hoogenboom, L.C.A.   +2 more
core   +1 more source

P937: PRECLINICAL DISCOVERY AND EARLY FINDINGS FROM THE PHASE 1, DOSE-ESCALATION STUDY OF WVT078, A BCMA-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH R/R MULTIPLE MYELOMA

, 2022
Marc‐Steffen Raab, Yaël C. Cohen, Fredrik Schjesvold, Kimberly Aardalen, Adwait Oka, Andrew Spencer, Martin Wermke, Parameswaran Hari, Jonathan L. Kaufman, Anna Maria Cafro, Enrique M. Ocio, N. Doki, Kristin L. Henson, Gina M. Trabucco, Pierre‐Éric Juif, R. Chawla, Jennifer L. Cotton, Adonai Fessehatsion, Lei Fan, John W. Blankenship, Brian Granda, Haihui Lu, Serena De Vita   +22 more
openalex   +1 more source

A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma [PDF]

, 2020
Yu Lin, Xi Yang, Nan Huang, Qiaoli Lang, Qi-Lin He, Jianhua Wang, Liangpeng Ge   +6 more
openalex   +1 more source